Research programme: adenosine A2A receptor antagonists - Advinus Therapeutics

Drug Profile

Research programme: adenosine A2A receptor antagonists - Advinus Therapeutics

Alternative Names: Ado A-2A receptor antagonist - Advinus; Ado A2AR antagonist - Advinus

Latest Information Update: 21 Jan 2016

Price : $50

At a glance

  • Originator Advinus Therapeutics
  • Class Antiparkinsonians; Neuroprotectants
  • Mechanism of Action Adenosine A2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Parkinson's disease

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 21 Jan 2016 Preclinical trials in Parkinson's disease in India (unspecified route)
  • 20 Jan 2016 Adenosine A2A receptor antagonist - Advinus Therapeutics is available for licensing as of 20 Jan 2016. http://www.advinus.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top